New hope for myelofibrosis patients: experimental pill targets resistant disease

NCT ID NCT06343805

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental oral drug, AJ1-11095, in about 76 adults with myelofibrosis (a type of bone marrow cancer) whose disease has stopped responding to standard JAK2 inhibitor therapy. The main goals are to check the drug's safety, find the best dose, and see if it can reduce symptoms and spleen size. Participants must have moderate-to-high risk disease and significant symptoms or spleen enlargement.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

platelet membrane fluidity primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AP-HP Hopital Saint-Louis

    RECRUITING

    Paris, France

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-••••

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering

    RECRUITING

    New York, New York, 10021, United States

    Contact

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    NOT_YET_RECRUITING

    Milan, Italy, Italy

    Contact

  • Genesis Cancer Care UK Limited - Oxford

    NOT_YET_RECRUITING

    Oxford, UK, United Kingdom

    Contact

  • Guy's Hospital

    NOT_YET_RECRUITING

    London, UK, United Kingdom

    Contact Phone: •••-•••-••••

  • Hospital Clinic Barcelona

    RECRUITING

    Barcelona, Spain

    Contact

  • Hospital General Universitario Gregorio Maranon

    RECRUITING

    Madrid, Spain, Spain

    Contact Phone: •••-•••-••••

  • Hospital Universitario Ramon y Cajal

    RECRUITING

    Madrid, Spain

    Contact

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

    NOT_YET_RECRUITING

    Bologna, Italy, Italy

    Contact

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Phone: •••-•••-••••

  • Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

    Contact Phone: •••-•••-••••

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-••••

  • Moffitt Cancer Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact Phone: •••-•••-••••

  • Stanford Cancer Institute

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-••••

  • The Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-••••

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45221, United States

    Contact Phone: •••-•••-••••

  • University of Kansas Medical Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-••••

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-••••